European Patent Office

T 0569/21 (Combination treatment for cystic fibrosis / VERTEX) du 07.12.2023

Identifiant européen de la jurisprudence
ECLI:EP:BA:2023:T056921.20231207
Date de la décision
7 décembre 2023
Numéro de l'affaire
T 0569/21
Requête en révision de
-
Numéro de la demande
15721912.2
Langue de la procédure
Anglais
Distribution
Non distribuées (D)
Téléchargement
Décision en anglais
Versions JO
Aucun lien JO trouvé
Autres décisions pour cet affaire
-
Résumés pour cette décision
-
Titre de la demande
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES
Nom du demandeur
Vertex Pharmaceuticals Incorporated
Nom de l'opposant
Generics (U.K.) Limited
Chambre
3.3.04
Sommaire
-
Dispositions juridiques pertinentes
European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal 2020 Art 012(5)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
Mots-clés
Main request - amendments - added subject-matter (no)
Main request - sufficiency of disclosure (yes)
Main request - novelty (yes)
Inventive step - (yes)
Inventive step - unexpected improvement shown
Objection of lack of inventive step - not substantiated - admitted (no)
Late-filed request - circumstances of appeal case justify admittance (yes)
Exergue
-
Affaires citées
G 0002/21T 0305/87
Affaires citantes
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division with the order to maintain the patent based on the following documents:

claims 1 to 21 of the main request submitted during the oral proceedings as new auxiliary request 1; the description and drawings possibly to be adapted thereto.